Skip to main content
IPCALAB · Health Care · 2026-08-21

IPCA Laboratories Ltd

5.7★ FairSolid +5.8Stage 2 · wk 33In scan: Breakout WatchMARKET: BULL RISING · 2026-08-21
₹1,911.2
+0.58% today
₹48,488 Cr · Large cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.

Visit company website →
P/E (TTM)
43.9
Forward 29.1
Earnings Growth (YoY)
+23.6%
Revenue +6.6%
Dividend Yield
0.25%
P/B 4.8
vs 52W High
0.0%
₹1,268.7 lo₹1,911.2 hi
Near 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 33
1w13w26w
Week 33 — mature, watch for distribution
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
23.3%
200 DMA: ₹1,549.9 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.46x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
MA20 flat · -0.2% vs MA50 +4.5%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
This stock ranks #25 of 84 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Ranks #20 of 58 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-26 → 2026-08-21
S2 43w
S2 24w
S2 33w
2023-05-262026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 8w → S1 5w → S2 43w → S3 7w → S2 24w → S3 8w → S4 9w → S1 4w → S4 3w → S1 9w → S4 10w → S1 5w → S2 33w current
Total tracked: 169 weeks across 13 stage runs.
1M
+7.9%
3M
+19.3%
6M
+27.8%
YTD
+32.7%
1Y
+38.8%
Scan Membership
Breakout Watch
Latest: 2026-01-01
2 appearances in last 60 days. First seen: 2024-08-16.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S2
Wk 33 · Vol x
2026-08-20S2
Wk 32 · Vol x
2026-08-19S2
Wk 32 · Vol x
2026-08-18S2
Wk 32 · Vol x
2026-08-17S2
Wk 32 · Vol x
2026-08-14S2
Wk 32 · Vol x
2026-08-13S2
Wk 31 · Vol x
2026-08-12S2
Wk 31 · Vol x
2026-08-11S2
Wk 31 · Vol x
2026-08-10S2
Wk 31 · Vol x
2026-08-07S2
Wk 31 · Vol x
2026-08-06S2
Wk 30 · Vol x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹1,745.7
200 DMA
₹1,549.9
52W High
₹1,911.2
52W Low
₹1,268.7
5D Low
₹1,882.1
Resistance levels (recent highs)
20d High
₹1,911.2
60d High
₹1,911.2
120d High
₹1,911.2
250d High
₹1,911.2
Next resistance
Above all

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.